Sector News

Merck offers EU concessions over $17 bln Sigma-Aldrich buy

May 28, 2015
Life sciences
(Reuters) – German drugmaker Merck has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp.
 
Earlier this month, Merck said the European Commission expressed concerns “of a limited nature” over its biggest ever takeover. It submitted concessions on May 22, according to a filing on the EU executive’s website. No details were provided.
 
The EU competition watchdog will now decide by June 15 instead of June 1 whether to approve the takeover.
 
Companies typically offer to sell overlapping assets or provide rivals access to technologies or patents to allay regulatory worries that the merged entity may have an excessive market share. (Reporting by Foo Yun Chee. Editing by Jane Merriman)

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend